510(k) Report

FDA applicant

Agendia BV

Amsterdam, NL8 decisions2007–20221 recall

FDA records 8 decisions for Agendia BV (Amsterdam, NL) from 2007 to 2022: 7 510(k) clearances and 1 De Novo grant. All are in product code NYI (Classifier, Prognostic, Recurrence Risk…). Its devices cite 7 predicates, 7 of them its own earlier devices. 1 recall is linked to its devices.

FDA’s records also spell it “Agendia”, “Agendia, Inc.”.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) refreshed weekly, last Nov 3, 2026

FIG. A — Illustration, immunology panel, where it files most

How often FDA has decided Agendia BV’s devices, and how often a recall has named them.

FDA decisions per year

1in 2022

2007: 22008: 12009: 12011: 12015: 12020: 12022: 1
2007high 2 (2007) · low 0 (2010)2026

2026 so far, outlined.

Recalls per year

1in 2010

2010: 1
2007high 1 (2010) · low 0 (2007)2026

Class I Class II/III not classified

FIG. 1 — Agendia BV by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports · Data through Oct 25, 2026

Planning a device like Agendia BV’s? A 510(k) Report ranks candidate predicates for your device by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report